The primary benefit of using TPO-RAs in cancer patients is the reduction in bleeding risk associated with thrombocytopenia. This allows for: - Continuation of chemotherapy or radiation therapy without delays. - Improved patient quality of life by reducing the need for platelet transfusions. - Potential for better overall treatment outcomes due to uninterrupted cancer therapy.